Samyang Biopharmaceuticals win patent trial of ‘Palseron’ against global pharmas

Published: 2018-01-05 16:27:00
Updated: 2018-01-05 16:09:32

Samyang Biopharmaceuticals(CEO Tae-Woong Um) announced on the 3rd the company has won the 1st trial of patent infringement related to ‘Palseron Inj(generic name: palonosetron hydrochloride)’ against Helsinn Healthcare SA., a global Swiss pharmaceutical company.

Last 21 December, Seoul Central Di...


- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Most Read News

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email:

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.